Used as a key chiral intermediate in the synthesis of biologically active compounds, particularly in pharmaceuticals targeting central nervous system disorders. Its structure, featuring a 2-methoxyethyl chain and a 4-(trifluoromethyl)phenyl moiety, supports the development of selective serotonin reuptake inhibitors (SSRIs) and other neuromodulatory agents. The presence of a trifluoromethyl group enhances metabolic stability and lipophilicity, improving blood-brain barrier penetration. Widely employed in asymmetric synthesis due to the chiral amine functionality, enabling the production of enantiomerically pure drugs. Also utilized in the preparation of radiolabeled derivatives for receptor binding studies.